ELAINE Trial Explores Lasofoxifene in ESR1+ Breast Cancer

Matthew P. Goetz, MD, discusses the current treatment landscape for patients with estrogen receptor-positive, HER2-negative breast cancer who harbor ESR1 mutations, and provided an overview of the ELAINE trial.

Read the full article here

Related Articles